175 related articles for article (PubMed ID: 28346360)
1. Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production.
Banning A; König JF; Gray SJ; Tikkanen R
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346360
[TBL] [Abstract][Full Text] [Related]
2. Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
Banning A; Schiff M; Tikkanen R
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):668-675. PubMed ID: 29247835
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
[TBL] [Abstract][Full Text] [Related]
5. Assignment of the aspartylglucosaminidase gene (AGA) to 4q33----q35 based on decreased activity in a girl with a 46,XX,del(4)(q33) karyotype.
Engelen J; Hamers A; Schrander-Stumpel C; Mulder H; Poorthuis B
Cytogenet Cell Genet; 1992; 60(3-4):208-9. PubMed ID: 1505217
[TBL] [Abstract][Full Text] [Related]
6. Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria.
Banning A; Gülec C; Rouvinen J; Gray SJ; Tikkanen R
Sci Rep; 2016 Nov; 6():37583. PubMed ID: 27876883
[TBL] [Abstract][Full Text] [Related]
7. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
Saarela J; von Schantz C; Peltonen L; Jalanko A
Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
[TBL] [Abstract][Full Text] [Related]
8. Aspartylglycosaminuria: a review.
Arvio M; Mononen I
Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
[TBL] [Abstract][Full Text] [Related]
9. In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation.
Ikonen E; Enomaa N; Ulmanen I; Peltonen L
Genomics; 1991 Sep; 11(1):206-11. PubMed ID: 1765378
[TBL] [Abstract][Full Text] [Related]
10. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse.
Virta S; Rapola J; Jalanko A; Laine M
J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877
[TBL] [Abstract][Full Text] [Related]
11. Dissection of the molecular consequences of a double mutation causing a human lysosomal disease.
Riikonen A; Ikonen E; Sormunen R; Lehto VP; Peltonen L; Jalanko A
DNA Cell Biol; 1994 Mar; 13(3):257-64. PubMed ID: 8172656
[TBL] [Abstract][Full Text] [Related]
12. Expression of aspartylglucosaminidase in human tissues from normal individuals and aspartylglucosaminuria patients.
Enomaa NE; Lukinmaa PL; Ikonen EM; Waltimo JC; Palotie A; Paetau AE; Peltonen L
J Histochem Cytochem; 1993 Jul; 41(7):981-9. PubMed ID: 7685790
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a point mutation in aspartylglucosaminidase gene: evidence for a readthrough of a translational stop codon.
Peltola M; Chiatayat D; Peltonen L; Jalanko A
Hum Mol Genet; 1994 Dec; 3(12):2237-42. PubMed ID: 7881426
[TBL] [Abstract][Full Text] [Related]
14. Deletion of the C-terminal end of aspartylglucosaminidase resulting in a lysosomal accumulation disease: evidence for a unique genomic rearrangement.
Jalanko A; Manninen T; Peltonen L
Hum Mol Genet; 1995 Mar; 4(3):435-41. PubMed ID: 7795599
[TBL] [Abstract][Full Text] [Related]
15. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
Enomaa N; Danos O; Peltonen L; Jalanko A
Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
[TBL] [Abstract][Full Text] [Related]
16. Expression and endocytosis of lysosomal aspartylglucosaminidase in mouse primary neurons.
Kyttälä A; Heinonen O; Peltonen L; Jalanko A
J Neurosci; 1998 Oct; 18(19):7750-6. PubMed ID: 9742145
[TBL] [Abstract][Full Text] [Related]
17. Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies.
Banning A; Laine M; Tikkanen R
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982794
[TBL] [Abstract][Full Text] [Related]
18. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
[TBL] [Abstract][Full Text] [Related]
19. The T99K variant of glycosylasparaginase shows a new structural mechanism of the genetic disease aspartylglucosaminuria.
Pande S; Guo HC
Protein Sci; 2019 Jun; 28(6):1013-1023. PubMed ID: 30901125
[TBL] [Abstract][Full Text] [Related]
20. Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder.
Harkke S; Laine M; Jalanko A
J Gene Med; 2003 Jun; 5(6):472-82. PubMed ID: 12797112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
